Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 71%-82% potential still at reach

<< Previous

Bullboard Posts

Next >>

Comment by LaserStock29on Apr 05, 2022 8:44am

257 Views

Post# 34575975

RE:RE:RE:RE:71%-82% potential still at reach

Been a long time since I posted here.. but yeah, the results look damn good.

And just a reminder.. there is no competition but ourselves.. we're having to prove Photodynamics against what was done in 1993-1998 (red light and no measurement of light) with modern technology (green light and measurement of light)

Im happy no patients died from covid... that's always a monkey wrench potential.....

the data is PURE... and it's in that 71-82% range that is very good..

now to get this to a 400m valuation asap.. $2 which is pittance for NMIBC.

ScienceFirst wrote:
We're still ahead of competition. With no side effects.

Fully optimized patients will keep increasing our efficacy % in both primary and secondary endpoints.

________________

enriquesuave - (4/5/2022 7:37:18 AM)

RE:RE:71%-82% potential still at reach

Excellent results as we beat Keytruda by far. 60% of evaluable patients are CR plus 17% are PR at 90 days vs 41% CR for Keytruda. I have stated before not to expect 100% CR and I expect similar results to Combination N803+ BCG which is about 42%CR at 12 months. Can we beat those numbers, perhaps as we have not yet seen enough of Optimized patients after 2nd optimized treatment. But if we are similar then we will be the best single agent and the best alternative overall. IMO looks promising